908 Devices (NASDAQ:MASS) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS

908 Devices (NASDAQ:MASS) issued its earnings results on Tuesday. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01, Zacks reports. The firm had revenue of $17.38 million during the quarter, compared to analysts’ expectations of $16.19 million. 908 Devices had a negative net margin of 7.17% and a negative return on equity of 22.31%.

Here are the key takeaways from 908 Devices’ conference call:

• Q4 revenue from continuing operations was $17.4 million, up 21% year‑over‑year, driven by demand for XplorIR, initial VipIR shipments, and strong U.S. state & local adoption.
• The company achieved positive adjusted EBITDA of $0.7 million in Q4 (vs. a loss of $4.0M a year ago) after cost and manufacturing consolidation, and targets cutting the 2025 adjusted EBITDA loss roughly in half in 2026 to the mid‑single‑digit millions.
• Product momentum is accelerating — shipped more than 40 VipIR units in Q4 (~$3M revenue) and delivered over 150 quant‑enabled XplorIR units in 2025 (XplorIR +40% YoY); the next‑gen MX908 platform is planned for commercial launch in 2026.
• Financial position strengthened with $113 million in cash and no debt, giving flexibility to invest in growth and support programs like AVCAD, for which the company expects $2M–$3M of revenue in 2026.
• Despite quarterly improvement, full‑year 2025 reported a net loss from continuing operations of $33.3 million and an adjusted EBITDA loss of $9.6 million, driven largely by non‑cash goodwill impairment and contingent consideration valuation changes, indicating ongoing profitability risks.

908 Devices Stock Performance

NASDAQ:MASS traded up $0.41 during trading hours on Wednesday, hitting $6.73. The stock had a trading volume of 104,174 shares, compared to its average volume of 326,113. 908 Devices has a one year low of $2.67 and a one year high of $9.34. The business’s 50 day moving average is $6.15 and its 200-day moving average is $6.64. The company has a market cap of $243.56 million, a price-to-earnings ratio of -61.18 and a beta of 0.47.

Insider Transactions at 908 Devices

In other news, CFO Joseph H. Iv Griffith sold 23,175 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $6.18, for a total transaction of $143,221.50. Following the completion of the sale, the chief financial officer owned 139,896 shares in the company, valued at approximately $864,557.28. This trade represents a 14.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 23.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On 908 Devices

A number of large investors have recently bought and sold shares of the stock. Raymond James Financial Inc. bought a new position in shares of 908 Devices during the 2nd quarter worth about $48,000. Daiwa Securities Group Inc. purchased a new stake in shares of 908 Devices during the 2nd quarter worth approximately $61,000. PCM Encore LLC purchased a new position in shares of 908 Devices during the 4th quarter valued at $62,000. The Manufacturers Life Insurance Company purchased a new stake in shares of 908 Devices in the second quarter worth $77,000. Finally, Walleye Capital LLC purchased a new position in 908 Devices during the second quarter worth about $82,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of 908 Devices in a research note on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, 908 Devices has an average rating of “Hold” and an average target price of $12.00.

More 908 Devices News

Here are the key news stories impacting 908 Devices this week:

• Positive Sentiment: Q4 results beat expectations — 908 Devices reported a loss of $0.05/share vs. Street -$0.06 and revenue of $17.38M vs. consensus $16.19M, showing sequential improvement in top-line execution. View Press Release
• Positive Sentiment: FY2026 revenue guidance slightly above consensus — management set revenue guidance of about $64.5M–$67.5M versus a consensus near $65.4M, which supports modest top-line growth expectations for the year. Article
• Neutral Sentiment: Conference materials and call transcripts are available for detailed read-through — management commentary and slide deck can clarify product pipeline and cadence of revenue. Listen to Conference Call View Slide Deck
• Neutral Sentiment: Short-interest reports flagged a “large increase” but the published figures are inconsistent (zeros/NaN) and appear unreliable — treat short-interest changes as noise until clarified by an official data source.
• Negative Sentiment: Company remains unprofitable and loss-making metrics persist — Q4 negative net margin (~-7.2%) and negative ROE (-22.3%); the company still expects FY results to be loss-making, which caps upside until sustained profitable growth is visible. Article
• Negative Sentiment: Management did not provide clear EPS guidance for FY2026 in the release (EPS guidance field left empty), which can increase near-term uncertainty for estimates and analyst modeling.

About 908 Devices

908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company’s core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices’ portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.